| Item type |
文献 / Documents(1) |
| 公開日 |
2025-01-16 |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_db06 |
|
資源タイプ |
doctoral thesis |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1016/j.clbc.2024.02.014 |
|
|
関連名称 |
10.1016/j.clbc.2024.02.014 |
| 出版タイプ |
|
|
出版タイプ |
NA |
|
出版タイプResource |
http://purl.org/coar/version/c_be7fb7dd8ff6fe43 |
| タイトル |
|
|
タイトル |
Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer |
| タイトル別表記 |
|
|
その他のタイトル |
手術可能乳がんにおけるS-1および低用量ドセタキセル併用化学療法の長期予後に関する研究 |
| タイトル別表記 |
|
|
その他のタイトル |
Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel |
| 著者 |
笹, 聡一郎
井上, 寛章
中川, 美砂子
鳥羽, 博明
後藤, 正和
Okumura, Kazumasa
Misaki, Mariko
乾, 友浩
Yukishige, Sawaka
Nishisho, Aya
Hino, Naoki
兼松, 美幸
坂東, 良美
上原, 久典
丹黒, 章
滝沢, 宏光
|
| 抄録 |
|
|
内容記述 |
Background: We previously reported that S-1 and low-dose docetaxel (DOC) (N-1 study, phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) for patients with operable breast cancer. Herein, we analyzed the long-term outcomes and developed clinicopathological and molecular predictors of pathological complete response (pCR). Patients and Methods: Eighty-three patients received S-1 (40 mg/m2 orally on days 1-14) and DOC (40 mg/m2 intravenously on day 1) every 3 weeks for 4 to 8 cycles. Disease-free survival (DFS) and overall survival (OS) were analyzed for each population with a pCR status. To assess the relationship between pCR and clinicopathological factors such as tumor-infiltrating lymphocytes (TILs, 1+ <10%, 2+ 10%-50%, and 3+ >50%) and nuclear grade (NG), microarray was used to compare the microRNA profiles of the pCR and non-pCR groups using core needle biopsy specimens. Results: With a median follow-up duration of 99.0 (range, 9.0-129.0) months, the 5-year DFS and OS rates were 80.7% and 90.9%, respectively. The 5-year OS rate of the pCR group was significantly better than that of the non-pCR group (100% vs. 86.2%, p = .0176). Specifically, in triple-negative patients, the difference was significant (100% vs. 60.0%, p = .0224). Multivariate analysis revealed that high TILs (≥2–3+) and NG 2–3 independently predicted pCR. Microarray data revealed that 3 miRNAs (miR-215-5p, miR-196a-5p, and miR-196b-5p) were significantly upregulated in the pCR group. Conclusion: Our NAC regimen achieved favorable long-term outcomes and significantly improved OS in the pCR group. High TILs, NG 2–3, and some miRNAs may be predictors of pCR. |
| キーワード |
|
|
主題 |
Pathological complete response |
| キーワード |
|
|
主題 |
Tumor-infiltrating lymphocytes |
| キーワード |
|
|
主題 |
microRNAs |
| 書誌情報 |
en : Clinical Breast Cancer
巻 24,
号 5,
p. e350-e359.e2,
発行日 2024-02-22
|
| 収録物ID |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
19380666 |
| 収録物ID |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
15268209 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12794086 |
| 出版者 |
|
|
出版者 |
Elsevier |
| 備考 |
|
|
値 |
内容要旨・審査要旨・論文本文の公開
本論文は，著者Soichiro Sasaの学位論文として提出され，学位審査・授与の対象となっている。
学位授与者所属 : 徳島大学大学院医学研究科（医学専攻） |
| EID |
|
|
識別子 |
415735 |
| 言語 |
|
|
言語 |
eng |
| 報告番号 |
|
|
学位授与番号 |
甲第3860号 |
| 学位記番号 |
|
|
値 |
甲医第1622号 |
| 学位授与年月日 |
|
|
学位授与年月日 |
2024-11-28 |
| 学位名 |
|
|
学位名 |
博士（医学） |
| 学位授与機関 |
|
|
|
学位授与機関名 |
徳島大学 |
k3860_abstract.pdf (133 KB)
